Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying

Research output: Contribution to journalArticle

2 Downloads (Pure)

Abstract

Drug-eluting stents are now routinely used in the treatment of acute coronary syndromes caused by coronary artery disease. Whilst the sustained release of anti-proliferative drugs from these devices has greatly reduced the need for repeat revascularisation procedures, this approach is not suitable for all patients and appears to delay regrowth of the endothelium, necessitating the use of prolonged dual anti-platelet therapy. Although the development of more advanced stent platforms and drug coatings has produced modest improvements in performance, these devices have not fully addressed the limitations experienced with their first-generation counterparts. In the present study, we developed a novel stent coating that provides controlled sirolimus release from a bioactive polymer (accelerate™ AT) that has previously been shown to support endothelial cell growth in vitro. A bespoke electrospray deposition process provided control over the coating thickness, surface roughness, drug load, and release kinetics. The resultant optimised coating combines rapid release of an anti-proliferative agent from a bioactive polymer coating that promotes re-endothelialisation, thereby offering potential protection against in-stent restenosis and thrombosis. This novel, dual-action coating therefore has significant therapeutic potential, with the enhanced control of drug load and release kinetics offered by electrospray deposition also opening up opportunities for more personalised treatment approaches. Further development and evaluation of these technologies in vitro and in vivo is therefore warranted.

Original languageEnglish
Pages (from-to)271-281
Number of pages11
JournalAnnals of Biomedical Engineering
Volume48
Issue number1
Early online date22 Aug 2019
DOIs
Publication statusPublished - 1 Jan 2020

Fingerprint

Drug-Eluting Stents
Stents
Coatings
Polymers
Equipment and Supplies
Sirolimus
Therapeutics
Acute Coronary Syndrome
Pharmaceutical Preparations
Endothelium
Coronary Artery Disease
Kinetics
Thrombosis
Blood Platelets
Endothelial Cells
Endothelial cells
Cell growth
Platelets
Technology
Process control

Keywords

  • in-stent restenosis
  • drug-eluting stent
  • electrohydrodynamic spraying
  • drug release
  • stent-thrombosis

Cite this

@article{096d48b6726a4ebdae508c3686ccf15a,
title = "Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying",
abstract = "Drug-eluting stents are now routinely used in the treatment of acute coronary syndromes caused by coronary artery disease. Whilst the sustained release of anti-proliferative drugs from these devices has greatly reduced the need for repeat revascularisation procedures, this approach is not suitable for all patients and appears to delay regrowth of the endothelium, necessitating the use of prolonged dual anti-platelet therapy. Although the development of more advanced stent platforms and drug coatings has produced modest improvements in performance, these devices have not fully addressed the limitations experienced with their first-generation counterparts. In the present study, we developed a novel stent coating that provides controlled sirolimus release from a bioactive polymer (accelerate™ AT) that has previously been shown to support endothelial cell growth in vitro. A bespoke electrospray deposition process provided control over the coating thickness, surface roughness, drug load, and release kinetics. The resultant optimised coating combines rapid release of an anti-proliferative agent from a bioactive polymer coating that promotes re-endothelialisation, thereby offering potential protection against in-stent restenosis and thrombosis. This novel, dual-action coating therefore has significant therapeutic potential, with the enhanced control of drug load and release kinetics offered by electrospray deposition also opening up opportunities for more personalised treatment approaches. Further development and evaluation of these technologies in vitro and in vivo is therefore warranted.",
keywords = "in-stent restenosis, drug-eluting stent, electrohydrodynamic spraying, drug release, stent-thrombosis",
author = "McKittrick, {C. M.} and Cardona, {M. J.} and Black, {R. A.} and C. McCormick",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/s10439-019-02346-6",
language = "English",
volume = "48",
pages = "271--281",
journal = "Annals of Biomedical Engineering",
issn = "0090-6964",
number = "1",

}

Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying. / McKittrick, C. M.; Cardona, M. J.; Black, R. A.; McCormick, C.

In: Annals of Biomedical Engineering , Vol. 48, No. 1, 01.01.2020, p. 271-281.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying

AU - McKittrick, C. M.

AU - Cardona, M. J.

AU - Black, R. A.

AU - McCormick, C.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Drug-eluting stents are now routinely used in the treatment of acute coronary syndromes caused by coronary artery disease. Whilst the sustained release of anti-proliferative drugs from these devices has greatly reduced the need for repeat revascularisation procedures, this approach is not suitable for all patients and appears to delay regrowth of the endothelium, necessitating the use of prolonged dual anti-platelet therapy. Although the development of more advanced stent platforms and drug coatings has produced modest improvements in performance, these devices have not fully addressed the limitations experienced with their first-generation counterparts. In the present study, we developed a novel stent coating that provides controlled sirolimus release from a bioactive polymer (accelerate™ AT) that has previously been shown to support endothelial cell growth in vitro. A bespoke electrospray deposition process provided control over the coating thickness, surface roughness, drug load, and release kinetics. The resultant optimised coating combines rapid release of an anti-proliferative agent from a bioactive polymer coating that promotes re-endothelialisation, thereby offering potential protection against in-stent restenosis and thrombosis. This novel, dual-action coating therefore has significant therapeutic potential, with the enhanced control of drug load and release kinetics offered by electrospray deposition also opening up opportunities for more personalised treatment approaches. Further development and evaluation of these technologies in vitro and in vivo is therefore warranted.

AB - Drug-eluting stents are now routinely used in the treatment of acute coronary syndromes caused by coronary artery disease. Whilst the sustained release of anti-proliferative drugs from these devices has greatly reduced the need for repeat revascularisation procedures, this approach is not suitable for all patients and appears to delay regrowth of the endothelium, necessitating the use of prolonged dual anti-platelet therapy. Although the development of more advanced stent platforms and drug coatings has produced modest improvements in performance, these devices have not fully addressed the limitations experienced with their first-generation counterparts. In the present study, we developed a novel stent coating that provides controlled sirolimus release from a bioactive polymer (accelerate™ AT) that has previously been shown to support endothelial cell growth in vitro. A bespoke electrospray deposition process provided control over the coating thickness, surface roughness, drug load, and release kinetics. The resultant optimised coating combines rapid release of an anti-proliferative agent from a bioactive polymer coating that promotes re-endothelialisation, thereby offering potential protection against in-stent restenosis and thrombosis. This novel, dual-action coating therefore has significant therapeutic potential, with the enhanced control of drug load and release kinetics offered by electrospray deposition also opening up opportunities for more personalised treatment approaches. Further development and evaluation of these technologies in vitro and in vivo is therefore warranted.

KW - in-stent restenosis

KW - drug-eluting stent

KW - electrohydrodynamic spraying

KW - drug release

KW - stent-thrombosis

UR - https://link.springer.com/journal/volumesAndIssues/10439

U2 - 10.1007/s10439-019-02346-6

DO - 10.1007/s10439-019-02346-6

M3 - Article

VL - 48

SP - 271

EP - 281

JO - Annals of Biomedical Engineering

JF - Annals of Biomedical Engineering

SN - 0090-6964

IS - 1

ER -